Page last updated: 2024-12-05

evans blue

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Evans blue is an anionic dye that binds to albumin, the most abundant protein in blood plasma. It is used in research and medicine to study blood volume, vascular permeability, and to assess the integrity of the blood-brain barrier. It is also used as a diagnostic tool for various conditions, including tumors and inflammation.
Evans blue is synthesized by reacting 1-amino-8-naphthol-3,6-disulfonic acid with diazotized 2,4-dinitroaniline. The resulting dye is a blue-colored compound that is highly soluble in water and readily binds to albumin.
The effects of Evans blue are primarily related to its binding to albumin, which can influence the distribution and excretion of the dye. Evans blue is generally considered safe for use in research and medicine, but it can cause some adverse effects, such as allergic reactions or skin discoloration.
Evans blue is an important tool for studying vascular function, permeability, and blood flow. It is used in research to investigate the effects of drugs and other agents on the vascular system. Evans blue is also used in clinical settings to diagnose and monitor a variety of conditions, including tumors, inflammation, and blood clots.
Evans blue is studied because it is a safe and effective dye for tracking blood volume and vascular permeability. It is also used to assess the integrity of the blood-brain barrier, which is a critical barrier that protects the brain from harmful substances in the blood. Research on Evans blue is ongoing to further understand its properties and applications in medicine and research.'

Evans Blue: An azo dye used in blood volume and cardiac output measurement by the dye dilution method. It is very soluble, strongly bound to plasma albumin, and disappears very slowly. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Evans blue : An organic sodium salt that is the tetrasodium salt of 6,6'-{(3,3'-dimethyl[1,1'-biphenyl]-4,4'-diyl)bis[diazene-2,1-diyl]}bis(4-amino-5-hydroxynaphthalene-1,3-disulfonate). It is sometimes used as a counterstain, especially in fluorescent methods to suppress background autofluorescence. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID9409
CHEMBL ID1200712
CHEBI ID82467
MeSH IDM0007985

Synonyms (75)

Synonym
tetrasodium 6,6'-[(3,3'-dimethylbiphenyl-4,4'-diyl)di(e)diazene-2,1-diyl]bis(4-amino-5-hydroxynaphthalene-1,3-disulfonate)
ci direct blue 53
c.i. direct blue 53, tetrasodium salt
geigy-blau 536
evan's blue
geigy blue 536, med
diazol pure blue bf
nsc-8680
dye evans blue
314-13-6
evans blue
c.i. 23860
1,3-naphthalenedisulfonic acid, 6,6'-((3,3'-dimethyl(1,1'-biphenyl)-4,4'-diyl)bis(azo))bis(4-amino-5-hydroxy)-, tetrasodium salt
c.i. direct blue 53 tetrasodium salt
direct blue 53
modr prima 53 [czech]
c34h24n6na4o14s4
1,3-naphthalenedisulfonic acid, 6,6'-((3,3'-dimethyl(1,1'-biphenyl)-4,4'-diyl)bis(azo))bis(4-amino-5-hydroxy-, tetrasodium salt
blekit evansa [polish]
1,3-naphthalenedisulfonic acid, 6,6'-((3,3'-dimethyl-4,4'-biphenylylene)bis(azo))bis(4-amino-5-hydroxy-, tetrasodium salt
einecs 206-242-5
4,4'-bis(7-(1-amino-8-hydroxy-2,4-disulpho)naphthylazo)-3,3'-bitolyl, tetrasodium salt
modr evansova [czech]
4,4'-bis(1-amino-8-hydroxy-2,4-disulfo-7-naphthylazo)-3,3'-bitolyl, tetrasodium salt
evans blue, sodium salt
4,4'-bis(7-(1-amino-8-hydroxy-2,4-disulfo)naphthylazo)-3,3'-bitolyl, tetrasodium salt
4,4'-bis(1-amino-8-hydroxy-2,4-disulpho-7-naphthylazo)-3,3'-bitolyl, tetrasodium salt
ccris 167
tetrasodium 6,6'-(3,3'-dimethyl-(1,1'-biphenyl)-4,4'diyl)bis(azo)bis(4-amino-5-hydroxy-1,3-naphthalenedisulphonate)
CHEMBL1200712
direct blue 53 tetrasodium salt
E0197
AKOS005287327
HMS3264P03
C19422
tox21_113237
dtxcid102815
cas-314-13-6
dtxsid9022815 ,
tox21_110929
S4716
1,3-naphthalenedisulfonic acid, 6,6'-((3,3'-dimethyl(1,1'-biphenyl)-4,4'-diyl)bis(2,1-diazenediyl))bis(4-amino-5-hydroxy-, sodium salt (1:4)
blekit evansa
modr prima 53
evans blue [usp]
modr evansova
45pg892go1 ,
unii-45pg892go1
AKOS015903001
evans blue [vandf]
dye evans blue [vandf]
evans blue [who-dd]
evans blue [iarc]
evans blue [orange book]
evan's blue [mi]
azovan blue [mart.]
CCG-213687
CHEBI:82467 ,
tetrasodium 6,6'-{(3,3'-dimethyl[1,1'-biphenyl]-4,4'-diyl)bis[diazene-2,1-diyl]}bis(4-amino-5-hydroxynaphthalene-1,3-disulfonate)
6,6-[(3,3'-dimethyl[1,1'-biphenyl]-4,4'-diyl)bis(azo)bis[4-amino- 5-hydroxy-1,3-naphthalenedisulphonic acid] tetrasodium salt
6,6-[(3,3'-dimethyl[1,1'-biphenyl]-4, 4'-diyl)bis(azo)bis[4-amino-5-hydroxy-1,3-naphthalenedisulphonic acid] tetrasodium salt
HB0280
mfcd00004021
evansblue
tetrasodium 4-amino-6-[(e)-2-{4'-[(e)-2-(8-amino-1-hydroxy-5,7-disulfonaphthalen-2-yl)diazen-1-yl]-3,3'-dimethyl-[1,1'-biphenyl]-4-yl}diazen-1-yl]-5-hydroxynaphthalene-1,3-disulfonate
GS-6076
tetrasodium 6,6'-[(3,3'-dimethyl-4,4'-biphenyldiyl)bis(2,1-diazenediyl)]bis(4-amino-5-hydroxy-1,3-naphthalenedisulfonate)
sodium 6,6'-((3,3'-dimethyl-[1,1'-biphenyl]-4,4'-diyl)bis(diazene-2,1-diyl))bis(4-amino-5-hydroxynaphthalene-1,3-disulfonate)
direct blue 53; c.i. 23860
AMY22387
sodium 6,6'-(1e,1'e)-(3,3'-dimethylbiphenyl-4,4'-diyl)bis(diazene-2,1-diyl)bis(4-amino-5-hydroxynaphthalene-1,3-disulfonate)
tetrasodium;4-amino-6-[[4-[4-[(8-amino-1-hydroxy-5,7-disulfonatonaphthalen-2-yl)diazenyl]-3-methylphenyl]-2-methylphenyl]diazenyl]-5-hydroxynaphthalene-1,3-disulfonate
A875909
H10520
tetrasodium 4-amino-6-[(1e)-2-{4'-[(1e)-2-(8-amino-1-hydroxy-5,7-disulfonatonaphthalen-2-yl)diazen-1-yl]-3,3'-dimethyl-[1,1'-biphenyl]-4-yl}diazen-1-yl]-5-hydroxynaphthalene-1,3-disulfonate

Research Excerpts

Overview

Evans blue is an inert tracer that measures plasma volume in human subjects and vascular permeability in animal models. The Evans Blue assay is a popular method for the quantification of BBB disruption. Tc-Evansblue is a 'single dose' agent for lymphatic mapping combining radioactivity and blue dye for sentinel node identification.

ExcerptReferenceRelevance
"Evans blue is a dye that binds albumin."( An in vivo assay to test blood vessel permeability.
Chernoff, J; Radu, M, 2013
)
1.11
"Evans blue dye (EBD) is an inert tracer that measures plasma volume in human subjects and vascular permeability in animal models. "( Optimization of Evans blue quantitation in limited rat tissue samples.
Lai, TW; Wang, HL, 2014
)
2.19
"The Evans Blue assay is a popular method for the quantification of BBB disruption."( Comparison Evans Blue injection routes: Intravenous versus intraperitoneal, for measurement of blood-brain barrier in a mice hemorrhage model.
Chen, H; Kammer, J; Manaenko, A; Tang, J; Zhang, JH, 2011
)
1.24
"Tc-Evans blue is a 'single dose' agent for lymphatic mapping combining radioactivity and blue dye for sentinel node identification. "( The tissue distribution of Evans blue dye in a sheep model of sentinel node biopsy.
Chatterton, BE; Farshid, G; Green, M; Kollias, J; Tsopelas, C, 2006
)
1.25
"Evans blue dye, which acts as an adjuvant in mice to promote induction of cell-mediated immunity, was found earlier to apparently act contrarily and decrease tuberculoimmunity. "( Suppression of tuberculoimmunity in mice by Evans blue dye.
Crowle, AJ; May, MH, 1982
)
1.97
"Evans blue dye functions as an adjuvant with protein antigens in saline to induce cell-mediated immunological responses in mice. "( Evans blue dye adjuvant enhances delayed hypersensitivity while blocking immunity to Mycobacterium tuberculosis in mice.
Anderson, DW; Crowle, AJ, 1981
)
3.15
"Evans Blue is a specific inhibitor of this reaction and acts by inhibiting the binding of Factor VIII to the platelet surface."( Evans blue: a specific inhibitor of factor VIII-induced platelet agglutination.
Kirby, EP, 1975
)
2.42
"Evans blue, which is a structural analogue of suramin, exerted its inhibitory action largely by competing with the template.primer for the same binding site of the enzyme."( Differential inhibition of various deoxyribonucleic acid polymerases by Evans blue and aurintricarboxylic acid.
Balzarini, J; De Clercq, E; Nakane, H; Ono, K, 1988
)
1.23

Effects

Evans blue dye (EBD) has been used extensively as a marker of extravascular protein leakage. Evans blue dye has a high affinity for albumin and emits a red-orange fluorescence at a wavelength of 720 nm.

ExcerptReferenceRelevance
"Evans blue dye has a high affinity for albumin and emits a red-orange fluorescence at a wavelength of 720 nm."( Structural locus of transmucosal albumin efflux in canine ileum. A fluorescent study.
Cook, BH; Granger, DN; Taylor, AE, 1976
)
0.98
"Evans blue (EB) dye has owned a long history as a biological dye and diagnostic agent since its first staining application by Herbert McLean Evans in 1914. "( Evans Blue Dye: A Revisit of Its Applications in Biomedicine.
Chen, F; Ni, Y; Xue, X; Yao, L; Yu, P, 2018
)
3.37
"Evans blue dye has been chosen primarily because it is easy for the average laboratory to use."( An Optimized Evans Blue Protocol to Assess Vascular Leak in the Mouse.
Dempsey, EC; Harral, JW; Loomis, ZL; Wick, MJ, 2018
)
1.57
"Evans blue dye (EBD) has been used extensively as a marker of extravascular protein leakage. "( Evans blue dye in the assessment of permeability-surface area product in perfused rat lungs.
Chang, SW; Dallal, MM, 1994
)
3.17
"Evans blue dye has a high affinity for albumin and emits a red-orange fluorescence at a wavelength of 720 nm."( Structural locus of transmucosal albumin efflux in canine ileum. A fluorescent study.
Cook, BH; Granger, DN; Taylor, AE, 1976
)
0.98

Treatment

ExcerptReferenceRelevance
"Pretreatment with Evans blue 50 mg/kg 1 h earlier exhibited longer-term inhibitory effect on compound 48/80-induced arterial hypotension and systemic inflammation."( Pretreatment with Evans blue, a stimulator of BK(Ca) channels, inhibits compound 48/80-induced shock, systemic inflammation, and mast cell degranulation in the rat.
Chen, CL; Fu, YS; Huang, HT; Huang, SY; Kuo, SY; Lee, KZ; Lin, HY; Wen, ZH, 2015
)
1.07

Toxicity

ExcerptReferenceRelevance
" However, raising vitamin E levels did not protect against putative adverse effects of normally occurring oxidants."( Vitamin E ameliorates adverse effects of endothelial injury in brain arterioles.
Bei, RA; Brandt, RB; Chan, W; Nelson, GH; Rosenblum, WI, 1996
)
0.29
"All dyes demonstrated relatively safe viability profiles in both cell lines at surgically relevant concentrations and times."( Comparison of the in vitro safety of intraocular dyes using two retinal cell lines: a focus on brilliant blue G and indocyanine green.
Gonder, J; Hutnik, C; Liu, H; Proulx, A; Yuen, D, 2009
)
0.35
"Gingival overgrowth is an adverse side effect of cyclosporine A (CsA) in the treatment of transplanted patients."( Side effects of cyclosporine-A treatment in rats: gingival overgrowth and early hyperglycemia.
Catanzaro, OL; Labal, ES; Lauria, LC; Obregon, P; Rodriguez, RR, 2010
)
0.36
"Carbon nanotubes (CNTs) are a novel nanomaterial with wide potential applications; however the adverse effects of CNTs following environmental exposure have recently received significant attention."( Phytotoxicity of multi-walled carbon nanotubes on red spinach (Amaranthus tricolor L) and the role of ascorbic acid as an antioxidant.
Begum, P; Fugetsu, B, 2012
)
0.38
" The LD50 of Ts-DF venom was 51."( Another record of significant regional variation in toxicity of Tityus serrulatus venom in Brazil: a step towards understanding the possible role of sodium channel modulators.
Carneiro, FP; Guerrero-Vargas, JA; Mortari, MR; Oliveira, FN; Pimenta, AM; Santos, DM; Schwartz, EF, 2013
)
0.39
"As increasing variants of nanoparticles (NPs) are being used in various products, it has become apparent that size alone can no longer adequately explain the variety of generated toxic profiles."( Assessment of ZnO and SiO2 nanoparticle permeability through and toxicity to the blood-brain barrier using Evans blue and TEM.
An, SS; Bae, SO; Choi, CS; Hulme, J; Jeong, KH; Kang, MO; Kim, MK; Kim, YR; Lee, EK; Maeng, EH; Shim, KH, 2014
)
0.62

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic analysis revealed that there was a correlation between tumor weight and the rate constants of transfer from the poorly-perfused region to the well-perfused region, and between the rate constants of transfer from the well-perfused region to the venous outflow and dosing ratios into the well-perfused region."( Pharmacokinetic analysis of drug disposition after intratumoral injection in a tissue-isolated tumor perfusion system.
Hashida, M; Nomura, T; Saikawa, A; Sezaki, H; Takakura, Y; Yamashita, F, 1996
)
0.29
" Our study thus suggests that novel strategies for improving the delivery of macromolecular therapeutic agents to tumours should focus on enhancing the tumour blood supply, increasing the half-life of the therapeutic agent in the blood plasma and/or enhancing the volume of the extracellular space available to macromolecules rather than on increasing the permeability of the microvascular wall or improving diffusion conditions in the tumour interstitium."( Macromolecule uptake in human melanoma xenografts. relationships to blood supply, vascular density, microvessel permeability and extracellular volume fraction.
Bjornaes, I; Graff, BA; Rofstad, EK, 2000
)
0.31
" In this study Evans blue dye (EBD) was loaded into controlled-release polymers and its pharmacokinetic properties were determined in vitro and in vivo by using a rabbit model of SAH."( Pharmacokinetics of controlled-release polymers in the subarachnoid space after subarachnoid hemorrhage in rabbits.
Frazier, JL; Legnani, FG; Pradilla, G; Tamargo, RJ; Wang, PP, 2004
)
0.68
" The pharmacokinetic properties of EBD-EVAc polymers are comparable to those of antivasospasm agents that are successfully used in animal models of SAH."( Pharmacokinetics of controlled-release polymers in the subarachnoid space after subarachnoid hemorrhage in rabbits.
Frazier, JL; Legnani, FG; Pradilla, G; Tamargo, RJ; Wang, PP, 2004
)
0.32
"Clomipramine pharmacokinetic studies in hyperlipidaemic rats were performed with clomipramine continuous infusion."( Pharmacokinetics of clomipramine, an antidepressant, in poloxamer 407-induced hyperlipidaemic model rats.
Fukushima, K; Ito, Y; Kobuchi, S; Shibata, M; Sugioka, N; Takada, K, 2011
)
0.37
" A drug with a short half-life in the blood is less available at a target organ."( Novel "Add-On" Molecule Based on Evans Blue Confers Superior Pharmacokinetics and Transforms Drugs to Theranostic Agents.
Chen, H; Chen, X; Jacobson, O; Kiesewetter, DO; Liu, Y; Ma, Y; Niu, G; Weiss, ID; Wu, H, 2017
)
0.74
" When matched to gas volume dose, however, the circulation half-life was found to be independent of microbubble size."( Microbubble gas volume: A unifying dose parameter in blood-brain barrier opening by focused ultrasound.
Borden, MA; Fan, AC; Harvey, BK; Hinkle, JJ; Newman, J; Song, KH, 2017
)
0.46
" The aims of this study were to determine the opening effect of eucalyptol on the BBB in rats, to establish and validate a method for the determination of eucalyptol in brain tissue, and to reveal its brain pharmacokinetic characteristics."( Study on the opening effect of eucalyptol on the blood-brain barrier and its brain pharmacokinetics.
Chen, Y; Dao, L; Jiang, L; Sa, C, 2023
)
0.91

Compound-Compound Interactions

ExcerptReferenceRelevance
" However, the tumors administered with a initial dose of CX at 24-h post-PDT had no tumor control."( Anti-angiogenic effects of Hypericin-photodynamic therapy in combination with Celebrex in the treatment of human nasopharyngeal carcinoma.
Olivo, M; Soo, KC; Yee, KK, 2005
)
0.33
"This research was designed to determine whether disrupting the blood-brain barrier (BBB) in rats by applying focused ultrasound (FUS) combined with microbubbles induced changes in the density of caveolae and/or the expression of the structural protein caveolin-1."( The role of caveolin-1 in blood-brain barrier disruption induced by focused ultrasound combined with microbubbles.
Cheng, Y; Deng, J; Huang, Q; Lei, B; Liu, Y; Wang, F; Wang, Z; Zhang, Q, 2012
)
0.38
"Focused ultrasound (FUS) combined with microbubbles (MBs) has emerged as a potential approach for opening the blood-brain barrier (BBB) for delivering drugs into the brain."( Biosynthetic Gas Vesicles Combined with Focused Ultrasound for Blood-Brain Barrier Opening.
Du, L; He, L; He, W; Li, Y; Shen, Y; Wang, Y; Yan, F; Yu, T; Zhang, J; Zhang, W; Zheng, S, 2022
)
0.72

Bioavailability

ExcerptReferenceRelevance
" The increase in absorption of poorly absorbed drugs could be ascribed to the increased permeability of the blood-gastric epithelium barrier as was evidenced by leakage of Evans Blue."( Characterization of mitomycin C-induced gastrointestinal damage: changes in the gastric absorption of drugs in rats.
Hashida, M; Kawabata, S; Mizuno, M; Sezaki, H, 1986
)
0.46
" The absolute bioavailability after vaginal administration of the 5% citric acid solution was 16."( Vaginal absorption of a potent luteinizing hormone-releasing hormone analogue (leuprolide) in rats II: mechanism of absorption enhancement with organic acids.
Mima, H; Okada, H; Yamazaki, I; Yashiki, T, 1983
)
0.27
" The vaginal absorption was enhanced by organic acids: citric, succinic, tartaric, and glycocholic; the absolute bioavailability increased to approximately 20%."( Vaginal absorption of a potent luteinizing hormone-releasing hormone analog (leuprolide) in rats I: absorption by various routes and absorption enhancement.
Hirai, S; Mima, H; Ogawa, Y; Okada, H; Yamazaki, I; Yashiki, T, 1982
)
0.26
" Thus, the increased subcutaneous bioavailability of hEGF in the presence of absorption promoters (except EDTA) was mainly attributed to the inhibitory effect of absorption promoters against the enzymic degradation of hEGF at the subcutaneous tissues."( Effect of absorption promoters on subcutaneous absorption of human epidermal growth factor in rats.
Amagase, H; Fuwa, T; Higashi, Y; Kojima, Y; Misaki, M; Murakami, T; Yamada, M; Yata, N; Yuki, M, 1993
)
0.29
" Thus, alterations in both plasma extravasation and tissue pH seem to be relevant factors regulating the delivery and bioavailability of this nonsteroidal anti-inflammatory drug to dental pulp."( Effect of inflammation on the delivery of drugs to dental pulp.
Bunczak-Reeh, MA; Hargreaves, KM, 1998
)
0.3
"The bioavailability of triprolidine from the ethylene vinyl acetate (EVA) matrix system containing polyoxyethylene-2-oleyl ether was studied to determine the feasibility of enhanced transdermal delivery of triprolidine in rabbits."( Enhanced efficacy of triprolidine by transdermal application of the EVA matrix system in rabbits and rats.
Choi, JS; Shin, SC, 2005
)
0.33
" Among the causative factors of BBB disruption are accelerating peroxynitrite formation and the resultant decreased bioavailability of nitric oxide (NO)."( The inhibitory effect of S-nitrosoglutathione on blood-brain barrier disruption and peroxynitrite formation in a rat model of experimental stroke.
Dhammu, TS; Gilg, AG; Khan, M; Sakakima, H; Shunmugavel, A; Singh, AK; Singh, I, 2012
)
0.38
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The aim of this dose-response study was to evaluate the effect of FBM after experimental SAH in rats. The blood-brain barrier (BBB) permeability changes were measured according to the extravasation of protein-bound Evans Blue.

ExcerptRelevanceReference
" This potentiation was critically dependent on the dosage of CGRP and was not observed when relatively high dosages were used."( Calcitonin gene-related peptide potentiates substance P-induced plasma extravasation in the rat trachea.
Brokaw, JJ; White, GW, 1992
)
0.28
" A dose-response study showed that giving 30 microliters of 20% mustard oil produced the maximal effect, with no further increase from 50 microliters."( Development of an orofacial model of acute inflammation in the rat.
Haas, DA; Hu, JW; Jordan, RC; MacMillan, RE; Nakanishi, O, 1992
)
0.28
" The slopes of the dose-response curves for all three compounds were linear and parallel, with statistically different potencies."( The effect of platelet-activating factor (PAF), histamine, and ethanol on vascular permeability of the guinea pig conjunctiva.
Kim, ED; Roth, SI; Stock, EL; Thamman, R; Walsh, MK, 1990
)
0.28
" The vaginal absorption from jellies, as practical dosage forms, yielded sufficient activity of leuprolide, but absorption was slightly reduced with highly polar polymers or with higher concentrations of polymers."( Vaginal absorption of a potent luteinizing hormone-releasing hormone analog (leuprolide) in rats I: absorption by various routes and absorption enhancement.
Hirai, S; Mima, H; Ogawa, Y; Okada, H; Yamazaki, I; Yashiki, T, 1982
)
0.26
" However SX6C was more potent than ETs and the dose-response curve was significantly steeper and achieved a higher maximum."( Actions of endothelins and sarafotoxin 6c in the rat isolated perfused lung.
Lal, H; Williams, KI; Woodward, B, 1995
)
0.29
") pretreatment shifted the bronchoconstrictor dose-response to capsaicin (0."( Evan's blue dye blocks capsaicin-induced cough and bronchospasm in the guinea pig.
Bolser, DC; Del Prado, M; Hey, JA; Mingo, G; O'Reilly, S, 1995
)
0.29
" PAF injected into the peritoneal cavity induced a bell-shaped dose-response curve of EB extravasation in both strains of mouse."( Differential sensitivity of mouse strains to platelet activating factor-induced vasopermeability and mortality: effect of antagonists.
Jancar, S; Russo, M; Vásquez-Bravo, YL, 1993
)
0.29
" Suramin (3 x 10(-5) M) caused a rightward shift of the dose-response curves for constriction caused by alpha, beta-methylene ATP (27-fold) and 2-methylthio ATP (5-fold), whereas the ATP curve was shifted to the left (20-fold)."( Characterization of vascular P2 purinoceptors in the rat isolated perfused kidney.
Eltze, M; Ullrich, B, 1996
)
0.29
" After surgical sympathectomy, the dose-response curve for bradykinin-induced plasma extravasation was significantly shifted to the right."( Sympathetic-dependence in bradykinin-induced synovial plasma extravasation is dose-related.
Coderre, TJ; Green, PG; Jänig, W; Levine, JD; Miao, FJ, 1996
)
0.29
" Pharmacokinetic analysis revealed that there was a correlation between tumor weight and the rate constants of transfer from the poorly-perfused region to the well-perfused region, and between the rate constants of transfer from the well-perfused region to the venous outflow and dosing ratios into the well-perfused region."( Pharmacokinetic analysis of drug disposition after intratumoral injection in a tissue-isolated tumor perfusion system.
Hashida, M; Nomura, T; Saikawa, A; Sezaki, H; Takakura, Y; Yamashita, F, 1996
)
0.29
" This was shown by a parallel shift of the agonist dose-response curves to the right."( In vivo effect of alpha 1-acid glycoprotein on experimentally enhanced capillary permeability in guinea-pig skin.
Linnau, Y; Muchitsch, EM; Pichler, L; Teschner, W,
)
0.13
" Dose-response curves obtained from glutamate activated whole cell currents yielded an IC50 value for EB of 13."( Differential modulation of AMPA receptor mediated currents by evans blue in postnatal rat hippocampal neurones.
Dietzel, ID; Lessmann, V; Schürmann, B; Wu, X, 1997
)
0.54
" Results showed a significantly improved skin perfusion in the lidocaine-treated group in a dose-response fashion as compared to control animals."( Local anesthetics improve dermal perfusion after burn injury.
Brofeldt, BT; Cassuto, J; Jönsson, A; Nellgård, P; Tarnow, P,
)
0.13
" There was no dose-response to intraperitoneal MP (up to 12 mg/kg) for nociceptive thresholds to heat (Peltier) or mechanical (analgesy-meter and von Frey fibers) stimuli in normal rats."( Methylprednisolone prevents the development of autotomy and neuropathic edema in rats, but has no effect on nociceptive thresholds.
Castellote, JM; Kingery, WS; Maze, M, 1999
)
0.3
" We report here that many parameters, such as anaesthesia, position of animal during and post delivery, and dosing schedule, must be optimized in concert with each other and that results from one species cannot be extrapolated directly to another animal model."( Tracking the tissue distribution of marker dye following intranasal delivery in mice and chinchillas: a multifactorial analysis of parameters affecting nasal retention.
Bakaletz, LO; Hjemdahl-Monsen, EJ; Novotny, LA; Thanavala, Y; Visweswaraiah, A, 2002
)
0.31
" All effects increased with increasing Optison dosage in the range 25 to 500 microL kg(-1)."( Impact of myocardial contrast echocardiography on vascular permeability: an in vivo dose response study of delivery mode, pressure amplitude and contrast dose.
Armstrong, WF; Cao, LQ; Dou, CY; Li, P; Miller, D, 2003
)
0.32
" Varying the infusion rate or trigger interval was less important than the overall dosage during scanning."( The influence of agent delivery mode on cardiomyocyte injury induced by myocardial contrast echocardiography in rats.
Armstrong, WF; Dou, C; Miller, DL, 2005
)
0.33
" The objective of this study was to improve in vivo tumor growth control of nasopharyngeal carcinoma (NPC), treated at a subcurative dosage by using a combination of Hypericin-PDT and COX-2 inhibitor, Celebrex (CX)."( Anti-angiogenic effects of Hypericin-photodynamic therapy in combination with Celebrex in the treatment of human nasopharyngeal carcinoma.
Olivo, M; Soo, KC; Yee, KK, 2005
)
0.33
" The aim of this dose-response study was to evaluate the effect of FBM after experimental SAH in rats on (1) behavioral deficits (employing a battery of assessment tasks days 1-5 post-injury) and (2) blood-brain barrier (BBB) permeability changes (quantifying microvascular alterations according to the extravasation of protein-bound Evans Blue by a spectrophotofluorimetric technique 2 days post-injury)."( NMDA receptor antagonist felbamate reduces behavioral deficits and blood-brain barrier permeability changes after experimental subarachnoid hemorrhage in the rat.
Angileri, FF; Arcadi, F; Bramanti, P; Caffo, M; Caruso, G; Costa, C; Germanò, A; Hayes, RL; Lewis, SB; Meli, F; Newcomb-Fernandez, J; Pineda, JA; Wang, KK, 2007
)
0.51
" The ability to optically monitor the BBB disruption in real-time could provide a feedback control for hypertonic disruption and/or facilitate dosage control for chemotherapeutic drugs that require such disruption."( Inconsistent blood brain barrier disruption by intraarterial mannitol in rabbits: implications for chemotherapy.
Bigio, IJ; Bruce, JN; Ergin, A; Joshi, S; Reif, R; Wang, M; Zhang, J, 2011
)
0.37
" Results of this study provide useful information for dosage adjustment of clomipramine in hyperlipidaemia."( Pharmacokinetics of clomipramine, an antidepressant, in poloxamer 407-induced hyperlipidaemic model rats.
Fukushima, K; Ito, Y; Kobuchi, S; Shibata, M; Sugioka, N; Takada, K, 2011
)
0.37
" (clinical periods, late donepezil treatment) with the dosage of 1, 2 and 4 mg/kg/d respectively and the treatments persisted throughout the experiments."( The anti-inflammatory effect of donepezil on experimental autoimmune encephalomyelitis in C57 BL/6 mice.
Chen, S; Chen, X; Jiang, Y; Kang, Z; Liu, M; Liu, Y; Ma, L; Ma, X; Peng, F; Pi, R; Wang, Q; Wu, A; Zhu, C; Zhu, D; Zou, Y, 2013
)
0.39
" We first demonstrated precise targeting and a linear dose-response of Evans Blue dye extravasation to the rat striatum for a set of constant microbubble and ultrasound parameters."( Microbubble gas volume: A unifying dose parameter in blood-brain barrier opening by focused ultrasound.
Borden, MA; Fan, AC; Harvey, BK; Hinkle, JJ; Newman, J; Song, KH, 2017
)
0.69
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
histological dyeA dye used in microscopic or electron microscopic examination of cells and tissues to give contrast and to highlight particular features of interest, such as nuclei and cytoplasm.
fluorochromeA fluorescent dye used to stain biological specimens.
teratogenic agentA role played by a chemical compound in biological systems with adverse consequences in embryo developments, leading to birth defects, embryo death or altered development, growth retardation and functional defect.
sodium channel blockerAn agent that inhibits sodium influx through cell membranes.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
organic sodium salt
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (20)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency16.50730.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency12.52830.000221.22318,912.5098AID743035; AID743042; AID743054; AID743063
estrogen nuclear receptor alphaHomo sapiens (human)Potency24.85070.000229.305416,493.5996AID743079; AID743080; AID743091
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency26.60320.001723.839378.1014AID743083
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency26.71350.000323.4451159.6830AID743065; AID743067
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency13.33320.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency13.33320.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Luciferin 4-monooxygenasePhotinus pyralis (common eastern firefly)IC50 (µMol)11.04000.05893.142610.0000AID328181; AID328182; AID328183; AID328185; AID328186
60 kDa heat shock protein, mitochondrialHomo sapiens (human)IC50 (µMol)0.17000.17004.559010.0000AID1594139
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)IC50 (µMol)1.30000.00053.49849.7600AID157217
Tyrosine-protein phosphatase 1Saccharomyces cerevisiae S288CIC50 (µMol)1.20001.20004.30007.4000AID220230
10 kDa heat shock protein, mitochondrialHomo sapiens (human)IC50 (µMol)0.17000.17004.559010.0000AID1594139
Ectonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)IC50 (µMol)0.92200.00111.095810.0000AID472450
Ectonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)Ki0.82400.10000.93801.8900AID472451
Thiosulfate sulfurtransferaseHomo sapiens (human)IC50 (µMol)8.70000.06003.96319.7000AID1594135
60 kDa chaperonin Escherichia coliIC50 (µMol)0.06300.03903.55529.8000AID1594140; AID1594141
10 kDa chaperonin Escherichia coliIC50 (µMol)0.06300.03903.55529.8000AID1594140; AID1594141
Vesicular glutamate transporter 3Rattus norvegicus (Norway rat)Ki0.04000.04000.11500.1900AID216240
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AlbuminHomo sapiens (human)Kd2.50000.08933.31358.0000AID1758625
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (141)

Processvia Protein(s)Taxonomy
cellular response to starvationAlbuminHomo sapiens (human)
negative regulation of mitochondrial depolarizationAlbuminHomo sapiens (human)
cellular response to calcium ion starvationAlbuminHomo sapiens (human)
cellular oxidant detoxificationAlbuminHomo sapiens (human)
transportAlbuminHomo sapiens (human)
protein folding60 kDa chaperoninEscherichia coli K-12
response to radiation60 kDa chaperoninEscherichia coli K-12
response to heat60 kDa chaperoninEscherichia coli K-12
virion assembly60 kDa chaperoninEscherichia coli K-12
chaperone cofactor-dependent protein refolding60 kDa chaperoninEscherichia coli K-12
protein refolding60 kDa chaperoninEscherichia coli K-12
chaperone cofactor-dependent protein refolding60 kDa chaperoninEscherichia coli K-12
response to heat60 kDa chaperoninEscherichia coli K-12
adhesion of symbiont to host60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of type II interferon production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
MyD88-dependent toll-like receptor signaling pathway60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of T cell mediated immune response to tumor cell60 kDa heat shock protein, mitochondrialHomo sapiens (human)
'de novo' protein folding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to unfolded protein60 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to cold60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interferon-alpha production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of type II interferon production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-10 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-12 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-6 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein refolding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
B cell proliferation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
B cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of macrophage activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
negative regulation of apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
isotype switching to IgG isotypes60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein stabilization60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
chaperone-mediated protein complex assembly60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein maturation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
biological process involved in interaction with symbiont60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cellular response to interleukin-760 kDa heat shock protein, mitochondrialHomo sapiens (human)
T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein import into mitochondrial intermembrane space60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial unfolded protein response60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apoptotic mitochondrial changes60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to lipopolysaccharideNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
apoptotic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
inflammatory responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
canonical NF-kappaB signal transductionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
JNK cascadeNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of gene expressionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of lipid storageNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of calcidiol 1-monooxygenase activityNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of vitamin D biosynthetic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of cholesterol transportNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of interleukin-12 productionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
response to muscle stretchNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
non-canonical NF-kappaB signal transductionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of apoptotic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of inflammatory responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
B cell receptor signaling pathwayNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of protein metabolic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
mammary gland involutionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of transcription initiation by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to mechanical stimulusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to nicotineNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to interleukin-1Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to interleukin-6Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to tumor necrosis factorNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to dsRNANuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to interleukin-17Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to virusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
antibacterial innate immune responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of hyaluronan biosynthetic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to angiotensinNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of miRNA metabolic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to stressNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
innate immune responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
response to cytokineNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
osteoblast differentiation10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process10 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to unfolded protein10 kDa heat shock protein, mitochondrialHomo sapiens (human)
chaperone cofactor-dependent protein refolding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
chemotaxisEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
immune responseEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
phospholipid catabolic processEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
positive regulation of epithelial cell migrationEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
vesicle-mediated transportEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
sphingolipid catabolic processEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
regulation of cell migrationEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
phosphatidylcholine catabolic processEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
cell motilityEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
positive regulation of lamellipodium morphogenesisEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
sulfur amino acid catabolic processThiosulfate sulfurtransferaseHomo sapiens (human)
cyanate catabolic processThiosulfate sulfurtransferaseHomo sapiens (human)
epithelial cell differentiationThiosulfate sulfurtransferaseHomo sapiens (human)
rRNA import into mitochondrionThiosulfate sulfurtransferaseHomo sapiens (human)
rRNA transportThiosulfate sulfurtransferaseHomo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (64)

Processvia Protein(s)Taxonomy
oxygen bindingAlbuminHomo sapiens (human)
DNA bindingAlbuminHomo sapiens (human)
fatty acid bindingAlbuminHomo sapiens (human)
copper ion bindingAlbuminHomo sapiens (human)
protein bindingAlbuminHomo sapiens (human)
toxic substance bindingAlbuminHomo sapiens (human)
antioxidant activityAlbuminHomo sapiens (human)
pyridoxal phosphate bindingAlbuminHomo sapiens (human)
identical protein bindingAlbuminHomo sapiens (human)
protein-folding chaperone bindingAlbuminHomo sapiens (human)
exogenous protein bindingAlbuminHomo sapiens (human)
enterobactin bindingAlbuminHomo sapiens (human)
magnesium ion binding60 kDa chaperoninEscherichia coli K-12
protein binding60 kDa chaperoninEscherichia coli K-12
ATP binding60 kDa chaperoninEscherichia coli K-12
isomerase activity60 kDa chaperoninEscherichia coli K-12
ATP hydrolysis activity60 kDa chaperoninEscherichia coli K-12
identical protein binding60 kDa chaperoninEscherichia coli K-12
unfolded protein binding60 kDa chaperoninEscherichia coli K-12
ATP-dependent protein folding chaperone60 kDa chaperoninEscherichia coli K-12
lipopolysaccharide binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
p53 binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
DNA replication origin binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
single-stranded DNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
RNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
double-stranded RNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
high-density lipoprotein particle binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
isomerase activity60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP hydrolysis activity60 kDa heat shock protein, mitochondrialHomo sapiens (human)
enzyme binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ubiquitin protein ligase binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apolipoprotein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apolipoprotein A-I binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
unfolded protein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-folding chaperone binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP-dependent protein folding chaperone60 kDa heat shock protein, mitochondrialHomo sapiens (human)
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
transcription cis-regulatory region bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
chromatin bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription factor activityNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
transcription coregulator activityNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
protein bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
identical protein bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
actinin bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
RNA binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding chaperone10 kDa heat shock protein, mitochondrialHomo sapiens (human)
unfolded protein binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-folding chaperone binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
metal ion binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
nucleic acid bindingEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
lysophospholipase activityEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
scavenger receptor activityEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
calcium ion bindingEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
zinc ion bindingEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
hydrolase activityEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
polysaccharide bindingEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
alkylglycerophosphoethanolamine phosphodiesterase activityEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
phosphodiesterase I activityEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
thiosulfate sulfurtransferase activityThiosulfate sulfurtransferaseHomo sapiens (human)
5S rRNA bindingThiosulfate sulfurtransferaseHomo sapiens (human)
3-mercaptopyruvate sulfurtransferase activityThiosulfate sulfurtransferaseHomo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (43)

Processvia Protein(s)Taxonomy
extracellular regionAlbuminHomo sapiens (human)
extracellular spaceAlbuminHomo sapiens (human)
nucleusAlbuminHomo sapiens (human)
endoplasmic reticulumAlbuminHomo sapiens (human)
endoplasmic reticulum lumenAlbuminHomo sapiens (human)
Golgi apparatusAlbuminHomo sapiens (human)
platelet alpha granule lumenAlbuminHomo sapiens (human)
extracellular exosomeAlbuminHomo sapiens (human)
blood microparticleAlbuminHomo sapiens (human)
protein-containing complexAlbuminHomo sapiens (human)
cytoplasmAlbuminHomo sapiens (human)
cytoplasm60 kDa chaperoninEscherichia coli K-12
cytosol60 kDa chaperoninEscherichia coli K-12
membrane60 kDa chaperoninEscherichia coli K-12
GroEL-GroES complex60 kDa chaperoninEscherichia coli K-12
mitochondrial matrix60 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular space60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cytoplasm60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrion60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial inner membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial matrix60 kDa heat shock protein, mitochondrialHomo sapiens (human)
early endosome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cytosol60 kDa heat shock protein, mitochondrialHomo sapiens (human)
plasma membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
clathrin-coated pit60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cell surface60 kDa heat shock protein, mitochondrialHomo sapiens (human)
membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
coated vesicle60 kDa heat shock protein, mitochondrialHomo sapiens (human)
secretory granule60 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular exosome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
sperm midpiece60 kDa heat shock protein, mitochondrialHomo sapiens (human)
sperm plasma membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
migrasome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-containing complex60 kDa heat shock protein, mitochondrialHomo sapiens (human)
lipopolysaccharide receptor complex60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial inner membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
extracellular regionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
nucleusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
nucleoplasmNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cytoplasmNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
mitochondrionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cytosolNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
secretory granule lumenNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
specific granule lumenNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
chromatinNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
transcription regulator complexNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
I-kappaB/NF-kappaB complexNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
nucleusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cytoplasmNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
NF-kappaB p50/p65 complexNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
mitochondrion10 kDa heat shock protein, mitochondrialHomo sapiens (human)
membrane10 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular exosome10 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial matrix10 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular spaceEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
plasma membraneEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
extracellular spaceEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
extracellular spaceThiosulfate sulfurtransferaseHomo sapiens (human)
mitochondrionThiosulfate sulfurtransferaseHomo sapiens (human)
mitochondrial matrixThiosulfate sulfurtransferaseHomo sapiens (human)
mitochondrionThiosulfate sulfurtransferaseHomo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (64)

Assay IDTitleYearJournalArticle
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347157Confirmatory screen GU Rhodamine qHTS for Zika virus inhibitors qHTS2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347164384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347156DAPI mCherry counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347163384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347158ZIKV-mCherry secondary qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1758625Binding affinity to human serum albumin assessed as dissociation constant by fluorescence emission spectrophotometric analysis2021European journal of medicinal chemistry, May-05, Volume: 217Using porphyrins as albumin-binding molecules to enhance antitumor efficacies and reduce systemic toxicities of antimicrobial peptides.
AID472464Inhibition of human recombinant C-terminal FLAG-tagged autotaxin expressed in baculovirus-infected Sf9 cells assessed as FS-3 hydrolysis at 30 uM2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors.
AID328184Inhibition of luciferase Photuris pennsylvanica by Promega Kinase-Glo assay2008Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8
Characterization of chemical libraries for luciferase inhibitory activity.
AID328181Inhibition of Photinus pyralis luciferase by PK-Light assay2008Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8
Characterization of chemical libraries for luciferase inhibitory activity.
AID472460Inhibition of human recombinant C-terminal FLAG-tagged autotaxin expressed in baculovirus-infected Sf9 cells assessed as FS-3 hydrolysis at 0.3 uM2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors.
AID472461Inhibition of human recombinant C-terminal FLAG-tagged autotaxin expressed in baculovirus-infected Sf9 cells assessed as FS-3 hydrolysis at 1 uM2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors.
AID1126820Inhibition of rat brain VGLUT assessed as inhibition of [3H]glutamate uptake into vesicles after 10 mins by scintillation spectrophotometry2014European journal of medicinal chemistry, May-06, Volume: 78Design, synthesis and biological evaluation of small-azo-dyes as potent Vesicular Glutamate Transporters inhibitors.
AID328193Inhibition of Photuris pyralis luciferase at 20 uM assessed as quenching of luminescence2008Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8
Characterization of chemical libraries for luciferase inhibitory activity.
AID1594142Selectivity index, ratio of IC50 for inhibition of native rhodanese (unknown origin) to IC50 for inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduct2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1594135Inhibition of native rhodanese (unknown origin) assessed as reduction in rhodanese enzyme activity after 45 mins by Fe(SCN)3 dye based spectrometric analysis2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID157217Inhibition of human PTPase 1B2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Evans Blue and other dyes as protein tyrosine phosphatase inhibitors.
AID1594134Inhibition of native soluble pig heart MDH assessed as reduction in MDH enzyme activity using sodium mesoxalate as substrate and NADH by malachite green dye based spectrometric analysis2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID472459Inhibition of human recombinant C-terminal FLAG-tagged autotaxin expressed in baculovirus-infected Sf9 cells assessed as FS-3 hydrolysis at 0.1 uM2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors.
AID328186Inhibition of Photinus pyralis luciferase by BrightGlo reporter gene assay2008Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8
Characterization of chemical libraries for luciferase inhibitory activity.
AID99424Inhibition of human Leukocyte Antigen Related(LAR) protein tyrosine phosphatase D12004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Evans Blue and other dyes as protein tyrosine phosphatase inhibitors.
AID1594138Selectivity index, ratio of IC50 for inhibition of native soluble pig heart MDH to IC50 for inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction i2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID328185Inhibition of Photinus pyralis luciferase by Steady-Glo reporter gene assay2008Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8
Characterization of chemical libraries for luciferase inhibitory activity.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID216240Evaluated for competitive inhibition against Vesicular glutamate transporter (VGLUT), and Ki value was reported.2002Journal of medicinal chemistry, May-23, Volume: 45, Issue:11
Synthesis and in vitro pharmacology of substituted quinoline-2,4-dicarboxylic acids as inhibitors of vesicular glutamate transport.
AID1808020Inhibition of porcine heart malate dehydrogenase preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec by spectrophotometric method2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID1692616Inhibition of ecto-ATPase in Wistar rat cardiac synaptosomes assessed as reduction in ATP hydrolysis at 100 uM preincubated for 10 min followed by ATP addition and measured after 6 mins relative to control2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Targeting Metabolism of Extracellular Nucleotides via Inhibition of Ectonucleotidases CD73 and CD39.
AID328194Inhibition of Renilla reniformis luciferase at 20 uM assessed as quenching of luminescence2008Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8
Characterization of chemical libraries for luciferase inhibitory activity.
AID1808021Inhibition of porcine heart malate dehydrogenase assessed as reduction in enzyme inhibition at 3 times IC50 preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec in presence of 0.01% Triton-X100 by spectrop2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID1594145Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity 2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID328187Inhibition of Renilla reniformis luciferase2008Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8
Characterization of chemical libraries for luciferase inhibitory activity.
AID472450Inhibition of human recombinant C-terminal FLAG-tagged autotaxin expressed in baculovirus-infected Sf9 cells assessed as FS-3 hydrolysis2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors.
AID472454Inhibition of human recombinant C-terminal FLAG-tagged NPP7 expressed in baculovirus-infected Sf9 cells assessed as pNPPC hydrolysis at 10 uM relative to control2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors.
AID1594143Selectivity index, ratio of IC50 for inhibition of native rhodanese (unknown origin) to IC50 for inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reducti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID472451Competitive inhibition of human recombinant C-terminal FLAG-tagged autotaxin expressed in baculovirus-infected Sf9 cells assessed as FS-3 hydrolysis by Michaelis-Menten method2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors.
AID1594139Inhibition of human N-terminal octa-His-tagged HSP60 expressed in Escherichia coli Rosetta(DE3) pLysS/human HSP10 expressed in Escherichia coli Rosetta(DE3) assessed as reduction in HSP60/HSP10-mediated denatured MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1594144Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1594136Selectivity index, ratio of IC50 for inhibition of native soluble pig heart MDH to IC50 for inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID32219Minimum inhibitory concentration of the compound, achieving a complete protection of ATH8 cells against the cytopathic effect of HTLV-III / LAV reverse transcriptase1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Chemotherapeutic approaches to the treatment of the acquired immune deficiency syndrome (AIDS).
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1594141Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID328183Inhibition of Photinus pyralis luciferase by Easy lite assay2008Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8
Characterization of chemical libraries for luciferase inhibitory activity.
AID1594140Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity 2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID32220Selectivity index expressed as ratio of compound concentration required to reduce the growth of normal uninfected ATH8 cells by 50% to the compound concentration (MIC)1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Chemotherapeutic approaches to the treatment of the acquired immune deficiency syndrome (AIDS).
AID472463Inhibition of human recombinant C-terminal FLAG-tagged autotaxin expressed in baculovirus-infected Sf9 cells assessed as FS-3 hydrolysis at 10 uM2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors.
AID1594137Inhibition of ATPase activity of Escherichia coli GroEL expressed in Escherichia coliDH5alpha incubated for 60 mins using ATP by spectrometric analysis2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID244292inhibitory effect on the DNA binding of Nuclear factor kappa B; Active2004Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24
Evans Blue is an inhibitor of nuclear factor-kappa B (NF-kappaB)-DNA binding.
AID220230Inhibitory activity against Saccharomyces cerevisiae Tyrosine phosphatase 12004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Evans Blue and other dyes as protein tyrosine phosphatase inhibitors.
AID1808023Inhibition of SARS-COV2 main protease using Ac-Abu-Tle-Leu-Gln-AFC as substrate by fluorescence assay2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID472458Inhibition of human recombinant C-terminal FLAG-tagged autotaxin expressed in baculovirus-infected Sf9 cells assessed as FS-3 hydrolysis at 0.03 uM2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors.
AID472462Inhibition of human recombinant C-terminal FLAG-tagged autotaxin expressed in baculovirus-infected Sf9 cells assessed as FS-3 hydrolysis at 3 uM2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors.
AID472449Inhibition of human recombinant C-terminal FLAG-tagged autotaxin expressed in baculovirus-infected Sf9 cells assessed as FS-3 hydrolysis at 10 uM relative to control2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID472456Inhibition of human recombinant C-terminal FLAG-tagged autotaxin expressed in baculovirus-infected Sf9 cells assessed as FS-3 hydrolysis at 0.003 uM2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors.
AID328182Inhibition of Photinus pyralis luciferase2008Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8
Characterization of chemical libraries for luciferase inhibitory activity.
AID472457Inhibition of human recombinant C-terminal FLAG-tagged autotaxin expressed in baculovirus-infected Sf9 cells assessed as FS-3 hydrolysis at 0.01 uM2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors.
AID472453Inhibition of human recombinant C-terminal FLAG-tagged NPP6 expressed in baculovirus-infected Sf9 cells assessed as pNPPC hydrolysis at 10 uM relative to control2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,025)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990523 (25.83)18.7374
1990's556 (27.46)18.2507
2000's487 (24.05)29.6817
2010's378 (18.67)24.3611
2020's81 (4.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 73.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index73.33 (24.57)
Research Supply Index7.66 (2.92)
Research Growth Index4.49 (4.65)
Search Engine Demand Index130.07 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (73.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials12 (0.57%)5.53%
Reviews14 (0.66%)6.00%
Case Studies9 (0.42%)4.05%
Observational1 (0.05%)0.25%
Other2,083 (98.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]